Peter Aksel Villadsen discusses how the Listen To This initiative is driving awareness of hearing health as essential to cognitive function, healthy aging, and overall wellbeing.
Regeneron’s DB-OTO gene therapy for genetic hearing loss is one of nine drugs to receive expedited review under FDA's new CNPV program.
HIA's MarkeTrak 2025 study of the U.S. hearing loss market provides new data on prescription hearing aids, OTC devices, and emerging technologies.
The award honors Nuance Audio’s achievement in combining hearing enhancement with fashionable, everyday eyewear.
The Audiology Practice Standards Organization is inviting public review and comment on its new draft standard to ensure profession-supported best practices in tinnitus evaluation.
Neuromod Devices has achieved both Medical Device Single Audit Program (MDSAP) and EU Medical Device Regulation (MDR) certification, enabling expanded global availability of its Lenire tinnitus treatment device in Europe, Canada, Australia, and beyond.
ESCO has appointed a new director of commercial insurance to lead its expanding suite of business coverage solutions.
A new study has identified how electrical charges in the inner ear trigger TMPRSS3-related hearing loss—and found that a common drug may help prevent it.
Doctoral students in Audiology from across the U.S. attended the 2025 Oticon Summer Camp for real-world clinical practice and career development.